PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas
- 1 March 2012
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 108 (3) , 375-383
Abstract
Increased lymphatic density correlates with lymph node metastases and survival in some epithelial cancers. The transcription factor, Prospero-related homeobox-gene 1, PROX1, plays an important role in the differentiation and proliferation of the lymphatic and nervous systems. We studied the clinicopathological significance of PROX1 expression in neuroblastomas (NBs) as the majority of patients have lymphatic and/or haematogenous metastases at diagnosis. PROX1-immunostained lymphatic vessels were present in 40/69 (58%) of NBs and 1/6 benign ganglioneuromas (GNs). Lymphatic density (LD) counts were significantly increased in NBs from patients with unfavourable clinical and pathological factors, and with distant lymph node metastases (LNM). Lymphatic invasion (LI) by tumoral emboli was present in 27/40 (68%) of NBs. A significantly higher proportion of LI was seen in undifferentiated/poorly-differentiated, (UD/PD) compared with differentiated NBs. LI was increased in NBs from patients with advanced-stage and high-risk group. Nuclear-PROX1 expression in tumoral cells was present in 35/69 (51%) NBs but was absent in all GNs. PROX1 expression was significantly higher in UD/PD compared with differentiated NBs. It was also higher in NBs with all adverse clinicopathological and biological variables. LI, PROX1 cellular expression and high LD correlated with a shorter overall survival and event-free survival (EFS). Multivariable Cox regression analysis showed that the effect of LD on both OS and EFS was independent of mitosis-karyorrhexis index and MYCN amplification. Increased LD, LI and cellular expression correlated with adverse factors in NBs. Increased LD correlated with LNM suggesting that PROX1 contributes to neuroblastoma progression and lymphatic spread.Keywords
This publication has 28 references indexed in Scilit:
- Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomasHistopathology, 2012
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2Clinical Cancer Research, 2010
- Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic GliomasJournal of Neuropathology & Experimental Neurology, 2010
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Angiogenesis as a target in neuroblastomaEuropean Journal of Cancer, 2008
- Transcription Factor PROX1 Induces Colon Cancer Progression by Promoting the Transition from Benign to Highly Dysplastic PhenotypeCancer Cell, 2008
- RNA mutations of prox1 detected in human esophageal cancer cells by the shifted termination assayBiochemical and Biophysical Research Communications, 2007
- First international consensus on the methodology of lymphangiogenesis quantification in solid human tumoursBritish Journal of Cancer, 2006
- Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992European Journal of Cancer, 2000